Observational Cohort Study of TachoSil (TC-018-IN)
Launched by NYCOMED · Feb 1, 2006
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All subjects, treated with TachoSil ® by the participating physicians, will be registered with a set of basic data from their already existing data (i.e. no additional diagnostic procedures will be performed).
- • Subjects who will provide their written informed consent to use existing data, allow direct access to data and data processing.
About Nycomed
Nycomed is a global pharmaceutical company dedicated to the development and commercialization of innovative medical solutions that enhance patient care. With a strong focus on improving health outcomes, Nycomed specializes in a diverse range of therapeutic areas, including respiratory, gastroenterology, and pain management. Committed to research and development, the company collaborates with healthcare professionals and stakeholders to advance clinical trials that contribute to the understanding and treatment of complex medical conditions. Nycomed’s mission is to deliver high-quality products that meet the evolving needs of patients and healthcare systems worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roskilde, , Denmark
Patients applied
Trial Officials
Nycomed Clinical Trial Operations
Study Chair
Headquarters
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials